These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 19627632)

  • 41. Rice-produced MSP142 of Plasmodium falciparum elicits antibodies that inhibit parasite growth in vitro.
    Chen Q; Liang W; Qian F; Qian B; Cao J; Zhang D; Xu Y; Tang L
    Parasite Immunol; 2016 Oct; 38(10):635-41. PubMed ID: 27493141
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Naturally acquired antibody responses to Plasmodium falciparum merozoite surface protein 4 in a population living in an area of endemicity in Vietnam.
    Wang L; Richie TL; Stowers A; Nhan DH; Coppel RL
    Infect Immun; 2001 Jul; 69(7):4390-7. PubMed ID: 11401978
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An engineered Plasmodium falciparum C-terminal 19-kilodalton merozoite surface protein 1 vaccine candidate induces high levels of interferon-gamma production associated with cellular immune responses to specific peptide sequences in Gambian adults naturally exposed to malaria.
    Bisseye C; Yindom LM; Simporé J; Morgan WD; Holder AA; Ismaili J
    Clin Exp Immunol; 2011 Dec; 166(3):366-73. PubMed ID: 22059995
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targets of complement-fixing antibodies in protective immunity against malaria in children.
    Reiling L; Boyle MJ; White MT; Wilson DW; Feng G; Weaver R; Opi DH; Persson KEM; Richards JS; Siba PM; Fowkes FJI; Takashima E; Tsuboi T; Mueller I; Beeson JG
    Nat Commun; 2019 Feb; 10(1):610. PubMed ID: 30723225
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dominance of conserved B-cell epitopes of the Plasmodium falciparum merozoite surface protein, MSP1, in blood-stage infections of naive Aotus monkeys.
    Hui GS; Nikaido C; Hashiro C; Kaslow DC; Collins WE
    Infect Immun; 1996 May; 64(5):1502-9. PubMed ID: 8613353
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of Plasmodium falciparum reticulocyte binding protein homologue 5-interacting protein, PfRipr, as a highly conserved blood-stage malaria vaccine candidate.
    Ntege EH; Arisue N; Ito D; Hasegawa T; Palacpac NMQ; Egwang TG; Horii T; Takashima E; Tsuboi T
    Vaccine; 2016 Nov; 34(46):5612-5622. PubMed ID: 27692771
    [TBL] [Abstract][Full Text] [Related]  

  • 47. RTS,S/AS01E immunization increases antibody responses to vaccine-unrelated Plasmodium falciparum antigens associated with protection against clinical malaria in African children: a case-control study.
    Dobaño C; Ubillos I; Jairoce C; Gyan B; Vidal M; Jiménez A; Santano R; Dosoo D; Nhabomba AJ; Ayestaran A; Aguilar R; Williams NA; Díez-Padrisa N; Lanar D; Chauhan V; Chitnis C; Dutta S; Gaur D; Angov E; Asante KP; Owusu-Agyei S; Valim C; Gamain B; Coppel RL; Cavanagh D; Beeson JG; Campo JJ; Moncunill G
    BMC Med; 2019 Aug; 17(1):157. PubMed ID: 31409398
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Influence of HLA-DRB1 alleles on antibody responses to PfCP-2.9-immunized and naturally infected individuals.
    Zhang Q; Xue X; Xu X; Wang C; Chang W; Pan W
    J Clin Immunol; 2009 Jul; 29(4):454-60. PubMed ID: 19247821
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antibody response dynamics to the Plasmodium falciparum conserved vaccine candidate antigen, merozoite surface protein-1 C-terminal 19kD (MSP1-19kD), in Peruvians exposed to hypoendemic malaria transmission.
    Torres KJ; Clark EH; Hernandez JN; Soto-Cornejo KE; Gamboa D; Branch OH
    Malar J; 2008 Sep; 7():173. PubMed ID: 18782451
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Functional Antibodies and Protection against Blood-stage Malaria.
    Teo A; Feng G; Brown GV; Beeson JG; Rogerson SJ
    Trends Parasitol; 2016 Nov; 32(11):887-898. PubMed ID: 27546781
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Plasmodium falciparum merozoite surface antigen-specific cytophilic IgG and control of malaria infection in a Beninese birth cohort.
    Adamou R; Dechavanne C; Sadissou I; d'Almeida T; Bouraima A; Sonon P; Amoussa R; Cottrell G; Le Port A; Theisen M; Remarque EJ; Longacre S; Moutairou K; Massougbodji A; Luty AJF; Nuel G; Migot-Nabias F; Sanni A; Garcia A; Milet J; Courtin D
    Malar J; 2019 Jun; 18(1):194. PubMed ID: 31185998
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Schistosomiasis coinfection in children influences acquired immune response against Plasmodium falciparum malaria antigens.
    Diallo TO; Remoue F; Gaayeb L; Schacht AM; Charrier N; De Clerck D; Dompnier JP; Pillet S; Garraud O; N'Diaye AA; Riveau G
    PLoS One; 2010 Sep; 5(9):e12764. PubMed ID: 20856680
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antibodies to the N-terminal block 2 of Plasmodium falciparum merozoite surface protein 1 are associated with protection against clinical malaria.
    Cavanagh DR; Dodoo D; Hviid L; Kurtzhals JA; Theander TG; Akanmori BD; Polley S; Conway DJ; Koram K; McBride JS
    Infect Immun; 2004 Nov; 72(11):6492-502. PubMed ID: 15501780
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Specific antibodies against Plasmodium falciparum antigens in immune subjects: II. Screening of responses against the merozoite major surface antigen (MSP!)].
    Nguer CM; Diouf A; Diallo TO; Dieye A; Tall A; Diouf B; Molez JF; Trape JF; Perraut R; Garraud O
    Dakar Med; 1997; 42(2):106-10. PubMed ID: 9827130
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adenovectors induce functional antibodies capable of potent inhibition of blood stage malaria parasite growth.
    Bruder JT; Stefaniak ME; Patterson NB; Chen P; Konovalova S; Limbach K; Campo JJ; Ettyreddy D; Li S; Dubovsky F; Richie TL; King CR; Long CA; Doolan DL
    Vaccine; 2010 Apr; 28(18):3201-10. PubMed ID: 20188680
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A robust neutralization test for Plasmodium falciparum malaria.
    Saul A; Miller LH
    J Exp Med; 2001 Jun; 193(12):F51-4. PubMed ID: 11413200
    [No Abstract]   [Full Text] [Related]  

  • 57. Antigenicity and immunogenicity of the N-terminal 33-kDa processing fragment of the Plasmodium falciparum merozoite surface protein 1, MSP1: implications for vaccine development.
    Yuen D; Leung WH; Cheung R; Hashimoto C; Ng SF; Ho W; Hui G
    Vaccine; 2007 Jan; 25(3):490-9. PubMed ID: 16949181
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Stability and potency of the Plasmodium falciparum MSP1-19/AMA-1(III) chimeric vaccine candidate with Montanide ISA720 adjuvant.
    Xue X; Ding F; Zhang Q; Pan X; Qu L; Pan W
    Vaccine; 2010 Apr; 28(18):3152-8. PubMed ID: 20197139
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Plasmodium falciparum anti-MSP1-19 antibodies induced by MSP1-42 and MSP1-19 based vaccines differed in specificity and parasite growth inhibition in terms of recognition of conserved versus variant epitopes.
    Hui G; Hashimoto C
    Vaccine; 2007 Jan; 25(5):948-56. PubMed ID: 17023096
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A DNA vaccine encoding the 42 kDa C-terminus of merozoite surface protein 1 of Plasmodium falciparum induces antibody, interferon-gamma and cytotoxic T cell responses in rhesus monkeys: immuno-stimulatory effects of granulocyte macrophage-colony stimulating factor.
    Kumar S; Villinger F; Oakley M; Aguiar JC; Jones TR; Hedstrom RC; Gowda K; Chute J; Stowers A; Kaslow DC; Thomas EK; Tine J; Klinman D; Hoffman SL; Weiss WW
    Immunol Lett; 2002 Apr; 81(1):13-24. PubMed ID: 11841841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.